Jasvir Kailey
Nurse Practitioner · Milwaukee, WINPI 1861946386
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$481
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$379
- Pfizer$365
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$332
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,375 |
| AstraZeneca | 55 | $1,001 |
| Lilly USA, LLC | 30 | $481 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $379 |
| Pfizer | 21 | $365 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $332 |
| Novo Nordisk | 13 | $242 |
| Ardelyx, Inc. | 10 | $215 |
| Johnson & Johnson | 8 | $214 |
| Phathom Pharmaceuticals, Inc. | 8 | $202 |
| Almatica Pharma LLC | 9 | $177 |
| Amgen | 6 | $137 |
| Kowa Pharmaceuticals America, Inc. | 8 | $129 |
| Boehringer Ingelheim | 7 | $120 |
| Ironwood Pharmaceuticals, Inc | 6 | $105 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Bayer | 4 | $93 |
| Aimmune Therapeutics, Inc. | 4 | $84 |
| GSK | 4 | $76 |
| Lundbeck LLC | 3 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Bausch Health US, LLC | 2 | $37 |
| Eisai Inc. | 2 | $33 |
| Viiv Healthcare Company | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Exact Sciences | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$6,219 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 99 | $108,177 |
| LinzessLinaclotide | 121 | $78,730 |
| FarxigaDapagliflozin Propanediol | 111 | $75,037 |
| JardianceEmpagliflozin | 55 | $46,016 |
| OzempicSemaglutide | 38 | $36,059 |
| MounjaroTirzepatide | 25 | $35,609 |
| VraylarCariprazine Hcl | 19 | $30,520 |
| CreonLipase/Protease/Amylase | 13 | $27,562 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,707 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $20,319 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $17,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $17,819 |
| UbrelvyUbrogepant | 13 | $16,030 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $14,817 |
| DapagliflozinDapagliflozin Propanediol | 26 | $13,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Vraylar, Creon, Ubrelvy, Savella | $1,375 | $164,110182 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $481 | $143,787124 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,001 | $113,587194 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $120 | $60,83384 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $76 | $38,13869 claims |
| Novo NordiskOzempic | $242 | $36,05938 claims |
| PfizerEliquis, Premarin | $365 | $18,86334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Other nurse practitioner in Milwaukee
- Trisha WilcoxMilwaukee$174K
- Christina SauldMilwaukee$111K
- Kelly FlugaurMilwaukee$38K
- Mathew TilsonMilwaukee$21K
- Mary Elizabeth Nelson-BiersachMilwaukee$18K
- Angela KrausMilwaukee$17K
- Megan LaneMilwaukee$14K
- Heather SandersMilwaukee$13K
- Cindy KoplitzMilwaukee$12K
- Cheryl BlaschukMilwaukee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.